Inactive Instrument

Kolinpharma S.p.A.

KIP

IT0005322950

Kolinpharma S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2021

September 27, 2021

Kolinpharma S.P.A. Announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was EUR 6.526 million compared to EUR 3.420 million a year ago. Net income was EUR 374,944 compared to net loss of EUR 127,668 a year ago.

Latest news about Kolinpharma S.p.A.

Kolinpharma presents supplement; patent application already filed	23-08-30	AN
Kolinpharma increases turnover in the first half of the year	23-07-28	AN
Igea Holding raises offer to take over Kolinpharma shares	23-07-28	AN
Kolinpharma suspends buyback plan after takeover bid by Igea Holding	23-06-28	AN
Kolinpharma S.p.A.'s Equity Buyback announced on May 15, 2023, has suspended.	23-06-27	CI
Kolinpharma S.p.A. commences an Equity Buyback Plan under the authorization approved on April 21, 2023.	23-05-14	CI
Kolinpharma, over 200,000 medical prescriptions in first quarter	23-05-04	AN
Kolinpharma S.p.A.'s Equity Buyback announced on April 28, 2022, has expired.	23-04-20	CI
Europeans up; Tenaris at bottom on Mib.	23-04-14	AN
Kolinpharma, profit halves in 2022 but revenue rises	23-03-22	AN
Kolinpharma S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Kolinpharma, prescriptions and whistleblowers grow in fourth quarter	23-02-07	AN
Kolinpharma S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-28	CI
Kolinpharma S.p.A.'s Equity Buyback announced on February 25, 2022, has expired.	22-04-27	CI
Kolinpharma S.p.A. commences an Equity Buyback Plan, under the authorization approved on April 28, 2022.	22-04-27	CI
Kolinpharma S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
Kolinpharma S.p.A. commences an Equity Buyback Plan, under the authorization approved on April 29, 2021.	22-02-25	CI
Kolinpharma S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-27	CI
Kolinpharma S.P.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-28	CI
An undisclosed buyer acquired 12.2% stake in Kolinpharma S.p.A. from Rita Paola Petrelli.	20-04-22	CI
RITA PAOLA PETRELLI acquired additional 19.2% stake in Kolinpharma S.p.A. from EMANUELE LUSENTI.	20-02-27	CI
Kolinpharma S.p.A. has completed an IPO in the amount of €3.129 million.	18-03-08	CI
Kolinpharma S.p.A. has filed an IPO.	18-02-07	CI

Chart Kolinpharma S.p.A.

Duration

Period

More charts

Company Profile

Kolinpharma SpA is an Italy-based company specialized in the pharmaceutical industry. The Company offers a number of products, including almetax, which is a food supplement based on alpha-lipoic acid, L-tryptophan, turmeric, vitamins B5, b6 AND C, Chromium picolinade and Zinc that acts synergistically on the main symptoms of menopause; Almatex easy, which enables the preservation of the general well-being of the body; Dolasix, which is a food supplement that acts synergistically in favor of the normal functionality of cartilages and connective tissues; Ivuxur, which is a food supplement based on cranberry ( dried cranberry extract), D-mannose, bearberry and Zinc that is used in the treatment of unary tract infections; Milesax, which is a food supplement based on magnesium bisglycinate, boswellia serrata and L-tryptophan that acts synergistically on contractures, muscles relaxation and mood during the rehabilitation and recovery phases, and Xinepa, among others.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+28.79%	676B
NOVO NORDISK A/S	+24.78%	554B
JOHNSON & JOHNSON	-7.64%	349B
MERCK & CO., INC.	+15.00%	318B
ABBVIE INC.	+5.99%	291B
ASTRAZENECA PLC	+3.28%	210B
NOVARTIS AG	-0.11%	204B
ROCHE HOLDING AG	-9.69%	194B
PFIZER, INC.	-11.71%	144B

Other Pharmaceuticals